Stoke Therapeutics, Inc. $STOK Shares Bought by Siren L.L.C.

Siren L.L.C. grew its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 12.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,247,347 shares of the company’s stock after buying an additional 247,347 shares during the period. Stoke Therapeutics accounts for approximately 0.9% of Siren L.L.C.’s holdings, making the stock its 28th biggest holding. Siren L.L.C.’s holdings in Stoke Therapeutics were worth $14,945,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Wellington Management Group LLP boosted its holdings in Stoke Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock valued at $904,000 after acquiring an additional 1,148 shares during the last quarter. Graham Capital Management L.P. raised its holdings in shares of Stoke Therapeutics by 8.5% in the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after purchasing an additional 1,453 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after purchasing an additional 2,215 shares in the last quarter. Group One Trading LLC lifted its stake in shares of Stoke Therapeutics by 2.8% in the 4th quarter. Group One Trading LLC now owns 104,411 shares of the company’s stock valued at $1,152,000 after purchasing an additional 2,837 shares in the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of Stoke Therapeutics by 16.2% during the 4th quarter. California State Teachers Retirement System now owns 32,068 shares of the company’s stock worth $354,000 after purchasing an additional 4,468 shares during the period.

Analyst Upgrades and Downgrades

STOK has been the topic of several research reports. Chardan Capital restated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $30.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Finally, BTIG Research set a $28.00 price target on Stoke Therapeutics and gave the company a “buy” rating in a report on Monday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and a consensus target price of $25.57.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $19.77 on Friday. The business has a 50-day moving average of $13.93 and a 200-day moving average of $10.64. The company has a market capitalization of $1.08 billion, a PE ratio of 23.26 and a beta of 1.15. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $19.97.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, equities analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the sale, the insider owned 25,782 shares in the company, valued at approximately $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jonathan Allan sold 13,712 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total transaction of $205,680.00. Following the transaction, the general counsel owned 19,631 shares in the company, valued at $294,465. This trade represents a 41.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,432 shares of company stock worth $345,775. 9.50% of the stock is currently owned by corporate insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.